RNA insider transaction filings
Atrium Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-04-22. Screen RNA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-22 | 4 | Kenney Stephanie — See Remarks | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Winslow Brendan R. — Chief Financial Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Hoyos Rocio Martin — Chief Strategy Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Younis Husam — Chief Scientific Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Gallagher Kathleen P. — See Remarks, Director | Grant/award (A): 102,500 @ $0 · Grant/award (A): 205,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Hughes Steven George — Chief Medical Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Skerjanec Simona — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Flanagan W. Michael — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Boyce Sarah — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | WILSON TROY EDWARD — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | BOESS CARSTEN — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Hughes Steven George — Chief Medical Officer | Sale (S): 2,017 @ $72.45 · Sale (S): 2,878 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | Boyce Sarah — President and CEO, Director | Sale (S): 6,394 @ $72.45 · Sale (S): 7,993 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | Flanagan W. Michael — Chief Scientific Officer | Sale (S): 3,976 @ $72.45 · Sale (S): 2,558 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | McCarthy Teresa — Chief Human Resources Officer | Sale (S): 1,476 @ $72.45 · Sale (S): 1,453 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | MacLean Michael F — Chief Financial Officer | Sale (S): 1,807 @ $72.45 · Sale (S): 2,735 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | LEVIN ARTHUR A — Director | Sale (S): 1,758 @ $72.45 | EDGAR |
| 2026-01-09 | 4 | Boyce Sarah — President and CEO, Director | Sale (S): 8,576 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | Calderaro Charles III — Chief Technical Officer | Sale (S): 3,727 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | McCarthy Teresa — Chief Human Resources Officer | Sale (S): 1,965 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | Hughes Steven George — Chief Medical Officer | Sale (S): 2,373 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | Flanagan W. Michael — Chief Scientific Officer | Sale (S): 2,373 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | Moriarty John B — Chief Legal Officer | Sale (S): 2,374 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | MacLean Michael F — Chief Financial Officer | Sale (S): 1,974 @ $72.23 | EDGAR |
| 2025-12-22 | 4 | LEVIN ARTHUR A — Director | Gift (G): 1,330 @ $0 | EDGAR |
| 2025-12-19 | 4 | Calderaro Charles III — Chief Technical Officer | Grant/award (A): 23,250 @ $0 · Tax withholding (F): 9,726 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | Flanagan W. Michael — Chief Scientific Officer | Grant/award (A): 27,500 @ $0 · Tax withholding (F): 13,695 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | Mosbrooker Eric — Chief Commercial Officer | Grant/award (A): 72,000 @ $0 · Tax withholding (F): 36,564 @ $71.87 · Tax withholding (F): 11,426 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | Boyce Sarah — President and CEO, Director | Grant/award (A): 31,000 @ $0 · Tax withholding (F): 15,742 @ $71.87 · Gift (G): 29,159 @ $0 | EDGAR |
| 2025-12-19 | 4 | Gallagher Kathleen P. — Chief Program Officer | Grant/award (A): 72,000 @ $0 · Tax withholding (F): 33,336 @ $71.87 · Tax withholding (F): 8,030 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | McCarthy Teresa — Chief Human Resources Officer | Grant/award (A): 39,000 @ $0 · Tax withholding (F): 17,298 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | Moriarty John B — Chief Legal Officer | Grant/award (A): 56,000 @ $0 · Tax withholding (F): 26,824 @ $71.87 | EDGAR |
| 2025-10-24 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 2,209 @ $10.16 · Sale (S): 2,209 @ $47.54 · Option exercise (M): 2,209 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | McCarthy Teresa — Chief Human Resources Officer | Option exercise (M): 20,000 @ $22.34 · Sale (S): 20,000 @ $50.15 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-10-07 | 4 | Mosbrooker Eric — Chief Commercial Officer | Option exercise (M): 6,562 @ $9.05 · Sale (S): 6,562 @ $45.38 · Option exercise (M): 6,562 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 2,208 @ $10.16 · Sale (S): 2,208 @ $40.58 · Option exercise (M): 2,208 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | McCarthy Teresa — Chief Human Resources Officer | Option exercise (M): 15,000 @ $22.34 · Sale (S): 15,000 @ $41.41 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 1,542 @ $6.57 · Sale (S): 1,542 @ $45.41 · Option exercise (M): 1,542 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Flanagan W. Michael — Chief Scientific Officer | Option exercise (M): 20,000 @ $14.22 · Sale (S): 20,000 @ $38.94 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-09 | 4 | WILSON TROY EDWARD — Director | Option exercise (M): 14,500 @ $12.48 · Sale (S): 14,500 @ $50 · Sale (S): 15,000 @ $50 · Option exercise (M): 14,500 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Boyce Sarah — President and CEO, Director | Option exercise (M): 50,000 @ $1.24 · Sale (S): 50,000 @ $49.95 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Mosbrooker Eric — Chief Commercial Officer | Option exercise (M): 6,563 @ $9.05 · Sale (S): 6,563 @ $47.07 · Option exercise (M): 6,563 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | Gallagher Kathleen P. — Chief Program Officer | Sale (S): 188 @ $47.42 | EDGAR |
| 2025-08-29 | 4 | Boyce Sarah — President and CEO, Director | Option exercise (M): 25,000 @ $1.24 · Sale (S): 25,000 @ $49.39 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 2,208 @ $10.16 · Sale (S): 2,208 @ $46.40 · Option exercise (M): 2,208 (derivative) @ $0 | EDGAR |
| 2025-08-15 | 4 | McCarthy Teresa — Chief Human Resources Officer | Option exercise (M): 10,000 @ $22.34 · Sale (S): 10,000 @ $46.56 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-08-15 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 1,542 @ $6.57 · Sale (S): 1,542 @ $46.66 · Option exercise (M): 1,542 (derivative) @ $0 | EDGAR |
| 2025-08-15 | 4 | MacLean Michael F — Chief Financial Officer | Sale (S): 30,914 @ $42.73 | EDGAR |
| 2025-08-08 | 4 | Mosbrooker Eric — Chief Commercial Officer | Option exercise (M): 124,687 @ $9.05 · Sale (S): 124,687 @ $44.06 · Sale (S): 6,120 @ $44.06 · Option exercise (M): 124,687 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 11,283 @ $15.96 · Sale (S): 11,283 @ $42.74 · Option exercise (M): 12,334 @ $6.57 · Sale (S): 12,334 @ $42.74 · Option exercise (M): 6,167 @ $22.47 · Sale (S): 6,167 @ $42.74 · +7 more | EDGAR |
Recent 8-K events — Atrium Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-02-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RNA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →